NCT00172120已完成3 期
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 91
- 试验地点
- 23
- 主要终点
- The primary objective of this study is to evaluate the safety of continued once-daily dosing with 100 mg ALX1-11 in postmenopausal osteoporotic women who participated in TOP and OLES clinical trials.
研究概览
简要总结
TRES will evaluate the effects of continued ALX1-11 treatment on the safety and efficacy variables assessed in the OLE study for a maximum treatment duration of 36 months in OLES and TRES combined.
详细描述
The primary goal of osteoporosis therapy is to prevent fracture, and anabolic agents can accomplish this by strengthening bone structure, which is accompanied by changes in BMD. Effects of ALX1-11 on BMD have been previously documented in a dose-finding Phase II clinical trial in osteoporotic postmenopausal women taking calcium and vitamin D supplements, who were otherwise naive to osteoporosis therapies. The anabolic effects of ALX1-11 on lumbar vertebrae were statistically significant compared to placebo after 12 months of treatment. In addition, animal studies showed that the new bone formed by treatment with ALX1 11 is of good quality both histologically and biomechanically (Mosekilde et al., 1991; Kimmel et al., 1993).
Protocol ALX1-11-93001 (TOP) assessed the effect of 18 months of ALX1-11 treatment on fracture incidence as a primary efficacy variable, and Protocol CL1-11-002 (OLES) assessed the effect on BMD for up to 24 months of treatment. Subjects who will be enrolled in the current study (TRES) will be those who received placebo in TOP and ALX1-11 in OLES. TRES will evaluate the effects of continued ALX1-11 treatment on the safety and efficacy variables assessed in the OLE study for a maximum treatment duration of 36 months in the OLES and TRES combined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Received placebo in TOP
- •Completed 18 months of daily treatment with ALX1-11 in OLES
- •Received their last dose of ALX1-11 in OLES within 3 months (90 days) of dosing in this study
- •Have the ability to continue to self-administer, or have a designee administer, a daily injection
- •Have the ability to understand, and willingness to sign, an informed consent form (ICF)
排除标准
- •Subjects are excluded who have developed any of the exclusion criteria for OLES, or modifications as listed below.
- •Concurrent Diseases Subjects are excluded if they have developed any of the diseases or illnesses listed since enrollment in OLES.
- •Immune.Significant* immunological disorders; including AIDSAllergies to ALX1-11 or its constituents
- •Endocrine.Significant* endocrine disorders, including hyper or hypoparathyroidism, Cushing's disease, hyperthyroidism
- •Gastrointestinal (GI).Significant* GI disorders
- •Kidney and Collecting.Significant* renal disorders or impaired renal function, nephrolithiasis or urolithiasis, verified kidney calcification, etc.
- •Liver, biliary tract, pancreatic.Significant* hepatic or pancreatic disorders, active hepatitis, or pancreatitis
- •Musculoskeletal.Metabolic bone disease, eg., Paget's disease, osteogenesis imperfecta, or osteomalacia -Chronic, active joint disease and/or joint infection
- •Neoplasia.Cancer, with the exception of squamous or basal cell carcinoma**
- •Nervous.Significant* neurological or psychiatric disease
- •Vascular, respiratory, and cardiac.Significant* unstable cardiac or pulmonary disease
- •(*)Significance will be determined by the investigator on the basis of history, physical exam, and/or laboratory screens. Significant disorders necessitate ongoing changes in therapeutic medication or frequent monitoring.
- •(**)Subjects who have had either squamous or basal cell carcinoma of the skin can enroll if:
- •The lesion(s) was fully resected with clear margins described in a written report by a pathologist, AND
- •The subject has had no recurrence of lesions for at least 1 year from the time of the original resection
- •Prohibited Concomitant Medications
- •PTH analogs*
- •Strontium
- •Calcitonin
- •Vitamin D metabolites or analogs(eg., calcitriol)
- •Immunomodulatory agents with antiproliferative activity
- •Cytostatics**
- •Thyroxine. Prohibited if dose > 0.2 mg/day (see Table 4-4 for allowed conditions)
- •Bisphosphonate
- •Anabolic steroids or androgens
- •(*)PTH (parathyroid hormone) analogs include PTH(1-34), PTHrP, and other analogs
- •(**)eg, azathioprine, recombinant human tumor necrosis fusion (Fc) protein, monoclonal antibody against tumor necrosis factor (e.g., infliximab [Remicade™])
- •Medications Requiring a Washout Period - Subjects who completed OLES and then began taking medications listed in the following table may enroll in this study after a washout period of 30 days.
- •Hormone-replacement therapy*
- •Methotrexate
- •SERMs**
- •Any investigational drug
- •Other medications known to affect the metabolism of bone
- •30 days with PMO approval
- •(*)Includes estrogen- and estrogen/progesterone-replacement therapy given by oral, transdermal, or intramuscular administration b SERMs (selective estrogen receptor modulator) include tamoxifen and raloxifene (Evista®) PMO = project medical officer
- •(**)SERMs (selective estrogen receptor modulator) include tamoxifen and raloxifene (Evista®) PMO = project medical officer
- •Medications Allowed if Specific Conditions Are Met-Medications that are allowed under specific conditions are listed:
- •Thyroid hormone. At a stable dose <= 0.2 mg/day
- •Thiazide. At a stable dose
- •Vaginal application of estrogen-containing creams. Conjugated estrogen or estradiol at a dose of <=0.5 g administered twice each week (total of 1.0 g weekly). Estrace® (Ogen)at a dose <=1.0 g twice each week (total of 2.0 g weekly)
- •Systemic corticosteroids. Acute bolus of steroids (oral or injectable) for a self-limited illness allowed under the following conditions:
- •Exposure to steroids limited to £30 consecutive days
- •Maximal dose (prednisone-equivalent) does not exceed 225 mg (5 mg/day for 30 days)
- •Illness was acute in nature and not expected to recur during the remaining treatment period of the study
- •Inhaled corticosteroids. At a dose <1200 mg/day beclomethasone equivalent
- •Intra-articular injections. A single intra-articular injection allowed every 6 months if the dose of corticosteroid injected is less than an equivalent dose of prednisone 40 mg suspension
- •Phenytoin. No phenytoin exposure allowed within 5 years of Month 0 of TOP. Allowed if last phenytoin exposure was >15 years prior to screening for TOP or was between 5-15 years before screening for TOP and for <2 months duration
- •Provera® (medroxyprogesterone). Allowed if used according to the label
- •Laboratory Values and Physical Examination Findings - For excluded laboratory values, the levels shown in the following table are the upper limits for exclusions based on specific test results, with the exception of calculated creatinine clearance and serum 25(OH) vitamin D, for which the limits are lower. All exclusionary laboratory results should be confirmed by a repeat test. Subjects may be excluded for any other clinically abnormal value, as determined by the investigator.
- •Fasting serum total calcium (Ca). Subject excluded if value* >10.2 mg/dL**,***
- 另有 10 项未显示
结局指标
主要结局
The primary objective of this study is to evaluate the safety of continued once-daily dosing with 100 mg ALX1-11 in postmenopausal osteoporotic women who participated in TOP and OLES clinical trials.
时间窗: Throughout the study period of approximately 18 months.
次要结局
- The secondary objective is to evaluate the continued efficacy of once-daily treatment with ALX1-11 for maintaining increases in bone mineral density (BMD).(Throughout the study period of approximately 18 months.)
研究者
研究点 (23)
Loading locations...
相似试验
终止
3 期
Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)Distal Myopathy With Rimmed VacuolesDistal Myopathy, Nonaka TypeGNE MyopathyQuadriceps Sparing MyopathyHereditary Inclusion Body MyopathyNCT02736188Ultragenyx Pharmaceutical Inc143
进行中（未招募）
2 期
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT04280718argenx229
已完成
3 期
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)AmyloidosisNCT02510261Alnylam Pharmaceuticals211
招募中
3 期
An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type IILeukocyte Adhesion DeficiencyNCT05754450AUG Therapeutics2
已完成
不适用
Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopneaObstructive Sleep Apnea HypopneaObstructive Sleep ApneaOSAHNCT00849043Ventus Medical, Inc.65